DK3528838T5 - Anvendelser af anti-IL-13-antistoffer til behandling af atopisk dermatitis - Google Patents
Anvendelser af anti-IL-13-antistoffer til behandling af atopisk dermatitis Download PDFInfo
- Publication number
- DK3528838T5 DK3528838T5 DK17780280.8T DK17780280T DK3528838T5 DK 3528838 T5 DK3528838 T5 DK 3528838T5 DK 17780280 T DK17780280 T DK 17780280T DK 3528838 T5 DK3528838 T5 DK 3528838T5
- Authority
- DK
- Denmark
- Prior art keywords
- antibodies
- treatment
- atopic dermatitis
- atopic
- dermatitis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662398713P | 2016-09-23 | 2016-09-23 | |
| US201762527204P | 2017-06-30 | 2017-06-30 | |
| US201762530683P | 2017-07-10 | 2017-07-10 | |
| US201762539037P | 2017-07-31 | 2017-07-31 | |
| PCT/US2017/052891 WO2018057849A1 (en) | 2016-09-23 | 2017-09-22 | Uses of il-13 antagonists for treating atopic dermatitis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DK3528838T3 DK3528838T3 (da) | 2023-08-28 |
| DK3528838T5 true DK3528838T5 (da) | 2024-09-02 |
Family
ID=60020628
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK17780280.8T DK3528838T5 (da) | 2016-09-23 | 2017-09-22 | Anvendelser af anti-IL-13-antistoffer til behandling af atopisk dermatitis |
Country Status (28)
| Country | Link |
|---|---|
| US (3) | US11434286B2 (enExample) |
| EP (2) | EP3528838B1 (enExample) |
| JP (1) | JP6995844B2 (enExample) |
| KR (1) | KR102557643B1 (enExample) |
| CN (1) | CN109715201A (enExample) |
| AU (1) | AU2017330405B2 (enExample) |
| CA (1) | CA3031589C (enExample) |
| CY (2) | CY1126255T1 (enExample) |
| DK (1) | DK3528838T5 (enExample) |
| ES (1) | ES2958593T3 (enExample) |
| FI (2) | FI3528838T3 (enExample) |
| FR (1) | FR24C1017I2 (enExample) |
| HR (1) | HRP20231015T1 (enExample) |
| HU (2) | HUE063135T2 (enExample) |
| IL (1) | IL265473B2 (enExample) |
| LT (2) | LT3528838T (enExample) |
| MX (1) | MX2019002672A (enExample) |
| NL (1) | NL301269I2 (enExample) |
| NZ (1) | NZ790629A (enExample) |
| PL (1) | PL3528838T3 (enExample) |
| PT (1) | PT3528838T (enExample) |
| RS (1) | RS64550B1 (enExample) |
| RU (1) | RU2752785C2 (enExample) |
| SG (1) | SG11201900845YA (enExample) |
| SI (1) | SI3528838T1 (enExample) |
| TW (1) | TWI787203B (enExample) |
| UA (1) | UA124269C2 (enExample) |
| WO (1) | WO2018057849A1 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA037960B1 (ru) | 2016-04-27 | 2021-06-15 | Эббви Инк. | Способ лечения эозинофильного эзофагита с применением антитела против il-13 |
| CA3031589C (en) * | 2016-09-23 | 2025-05-06 | Genentech, Inc. | USES OF IL-13 ANTAGONISTS FOR THE TREATMENT OF ATOPIC DERMATITIS |
| WO2021191220A1 (en) * | 2020-03-23 | 2021-09-30 | Medimmune Limited | Methods for treating atopic dermatitis and related disorders |
| US12187788B2 (en) * | 2020-03-23 | 2025-01-07 | Medimmune Limited | Methods for treating atopic dermatitis and related disorders |
| AU2021358274A1 (en) * | 2020-10-09 | 2023-05-25 | Kyowa Kirin Co., Ltd. | Method for treating ox40 related disease |
| TW202302104A (zh) * | 2021-02-18 | 2023-01-16 | 美商阿克拉里斯醫療股份有限公司 | Jak 1/3抑制劑的局部配方及其用於治療異位性皮膚炎和其他皮膚狀況之用法 |
| CA3208011A1 (en) * | 2021-03-17 | 2022-09-22 | Sarah Harris | Methods of treating atopic dermatitis with anti il-13 antibodies |
| TWI847170B (zh) * | 2021-07-16 | 2024-07-01 | 美商德米拉股份有限公司 | 用於治療異位性皮炎之il-13抗體 |
| TWI859566B (zh) * | 2021-08-13 | 2024-10-21 | 美商德米拉股份有限公司 | 用於治療異位性皮膚炎之il-13抗體 |
| IL311027A (en) * | 2021-09-15 | 2024-04-01 | Dermira Inc | Il-13 inhibitors for the treatment of prurigo nodularis |
| IL316779A (en) * | 2022-05-05 | 2025-01-01 | Dermira Inc | IL-13 antibodies for the treatment of atopic dermatitis |
| JP2025522482A (ja) | 2022-06-17 | 2025-07-15 | アポジー バイオロジクス， インコーポレイテッド | インターロイキン１３に結合する抗体及び使用方法 |
| EP4594352A1 (en) * | 2022-09-06 | 2025-08-06 | ASLAN Pharmaceuticals Pte Ltd | Treatment for sleep loss or sleep disturbance in patients with dermatitis |
| WO2024191249A1 (ko) | 2023-03-14 | 2024-09-19 | 주식회사 지오비스타 | 인터루킨-13에 특이적으로 결합하는 항체 및 그의 용도 |
| KR102773781B1 (ko) | 2023-03-14 | 2025-02-28 | 주식회사 지오비스타 | 인터루킨-13에 특이적으로 결합하는 항체 및 그의 용도 |
| GB202306662D0 (en) | 2023-05-05 | 2023-06-21 | Union Therapeutics As | Dosage regimen |
| KR20250017610A (ko) | 2023-07-27 | 2025-02-04 | 김천균 | 아토피의 치료와 예방용 조성물 및 그 제조방법 |
| WO2025049345A1 (en) | 2023-08-25 | 2025-03-06 | Proteologix Us Inc. | Anti-il-13 multispecific antibody constructs and uses thereof |
| US20250230251A1 (en) | 2023-12-20 | 2025-07-17 | Bristol-Myers Squibb Company | Antibodies targeting il-18 receptor beta (il-18rb) and related methods |
| WO2025155874A1 (en) * | 2024-01-18 | 2025-07-24 | Enveda Therapeutics, Inc. | Methods and compounds for modulating immune response |
| WO2025264960A1 (en) * | 2024-06-21 | 2025-12-26 | Apogee Therapeutics, Inc. | Antibodies that bind il-13 and antibodies that bind ox40l |
| WO2025264972A1 (en) * | 2024-06-21 | 2025-12-26 | Apogee Therapeutics, Inc. | Antibodies that bind il-4r alpha and antibodies that bind |
Family Cites Families (101)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| AU600575B2 (en) | 1987-03-18 | 1990-08-16 | Sb2, Inc. | Altered antibodies |
| FI903489A0 (fi) | 1988-11-11 | 1990-07-10 | Medical Res Council | Ligander med en enda sektion, receptorer innehaollande naemnda ligander, foerfaranden foer deras framstaellning samt anvaendning av liganderna och receptorerna. |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| DE69129154T2 (de) | 1990-12-03 | 1998-08-20 | Genentech, Inc., South San Francisco, Calif. | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
| US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
| EP0940468A1 (en) | 1991-06-14 | 1999-09-08 | Genentech, Inc. | Humanized antibody variable domain |
| GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
| EP0604580A1 (en) | 1991-09-19 | 1994-07-06 | Genentech, Inc. | EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES |
| FI941572L (fi) | 1991-10-07 | 1994-05-27 | Oncologix Inc | Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| DE69333807T2 (de) | 1992-02-06 | 2006-02-02 | Chiron Corp., Emeryville | Marker für krebs und biosynthetisches bindeprotein dafür |
| WO1994029351A2 (en) | 1993-06-16 | 1994-12-22 | Celltech Limited | Antibodies |
| US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
| US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| ES2244066T3 (es) | 1997-06-24 | 2005-12-01 | Genentech, Inc. | Procedimiento y composiciones de glicoproteinas galactosiladas. |
| US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
| EP1028751B1 (en) | 1997-10-31 | 2008-12-31 | Genentech, Inc. | Methods and compositions comprising glycoprotein glycoforms |
| US6610833B1 (en) | 1997-11-24 | 2003-08-26 | The Institute For Human Genetics And Biochemistry | Monoclonal human natural antibodies |
| AU760562B2 (en) | 1997-12-05 | 2003-05-15 | Scripps Research Institute, The | Humanization of murine antibody |
| DE69937291T2 (de) | 1998-04-02 | 2008-07-10 | Genentech, Inc., South San Francisco | Antikörpervarianten und fragmente davon |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| ES2434961T5 (es) | 1998-04-20 | 2018-01-18 | Roche Glycart Ag | Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo |
| KR101077001B1 (ko) | 1999-01-15 | 2011-10-26 | 제넨테크, 인크. | 효과기 기능이 변화된 폴리펩티드 변이체 |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| EP1176195B1 (en) | 1999-04-09 | 2013-05-22 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
| US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
| DE60022369T2 (de) | 1999-10-04 | 2006-05-18 | Medicago Inc., Sainte Foy | Verfahren zur regulation der transkription von fremden genen in gegenwart von stickstoff |
| AU7950400A (en) | 1999-10-19 | 2001-04-30 | Kyowa Hakko Kogyo Co. Ltd. | Process for producing polypeptide |
| WO2001044463A1 (en) | 1999-12-15 | 2001-06-21 | Genentech, Inc. | Shotgun scanning, a combinatorial method for mapping functional protein epitopes |
| ES2637801T3 (es) | 2000-04-11 | 2017-10-17 | Genentech, Inc. | Anticuerpos multivalentes y usos de los mismos |
| US7064191B2 (en) | 2000-10-06 | 2006-06-20 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| CN102311986B (zh) | 2000-10-06 | 2015-08-19 | 协和发酵麒麟株式会社 | 产生抗体组合物的细胞 |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| JP3523245B1 (ja) | 2000-11-30 | 2004-04-26 | メダレックス，インコーポレーテッド | ヒト抗体作製用トランスジェニック染色体導入齧歯動物 |
| RU2321630C2 (ru) | 2001-08-03 | 2008-04-10 | Гликарт Биотекнолоджи АГ | Гликозилированные антитела (варианты), обладающие повышенной антителозависимой клеточной цитотоксичностью |
| US20030157108A1 (en) | 2001-10-25 | 2003-08-21 | Genentech, Inc. | Glycoprotein compositions |
| US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
| US20050031613A1 (en) | 2002-04-09 | 2005-02-10 | Kazuyasu Nakamura | Therapeutic agent for patients having human FcgammaRIIIa |
| CN102911987B (zh) | 2002-04-09 | 2015-09-30 | 协和发酵麒麟株式会社 | 基因组被修饰的细胞 |
| WO2003084569A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Drug containing antibody composition |
| AU2003236018A1 (en) | 2002-04-09 | 2003-10-20 | Kyowa Hakko Kirin Co., Ltd. | METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcGamma RECEPTOR IIIa |
| US20040132140A1 (en) | 2002-04-09 | 2004-07-08 | Kyowa Hakko Kogyo Co., Ltd. | Production process for antibody composition |
| JP4628679B2 (ja) | 2002-04-09 | 2011-02-09 | 協和発酵キリン株式会社 | Ｇｄｐ−フコースの輸送に関与する蛋白質の活性が低下または欠失した細胞 |
| JP4753578B2 (ja) | 2002-06-03 | 2011-08-24 | ジェネンテック， インコーポレイテッド | 合成抗体ファージライブラリー |
| US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| ES2347241T3 (es) | 2002-12-16 | 2010-10-27 | Genentech, Inc. | Variantes de inmunoglobulina y sus utilizaciones. |
| US20050079574A1 (en) | 2003-01-16 | 2005-04-14 | Genentech, Inc. | Synthetic antibody phage libraries |
| US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
| US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
| US20080241884A1 (en) | 2003-10-08 | 2008-10-02 | Kenya Shitara | Fused Protein Composition |
| US20070134759A1 (en) | 2003-10-09 | 2007-06-14 | Harue Nishiya | Process for producing antibody composition by using rna inhibiting the function of alpha1,6-fucosyltransferase |
| ES2672640T3 (es) | 2003-11-05 | 2018-06-15 | Roche Glycart Ag | Moléculas de unión a antígeno con afinidad de unión a receptores Fc y función efectora incrementadas |
| WO2005053742A1 (ja) | 2003-12-04 | 2005-06-16 | Kyowa Hakko Kogyo Co., Ltd. | 抗体組成物を含有する医薬 |
| DK2805728T3 (da) | 2003-12-23 | 2020-04-20 | Genentech Inc | Hidtil ukendte anti-IL13-antistoffer og anvendelser deraf |
| RU2386638C2 (ru) | 2004-03-31 | 2010-04-20 | Дженентек, Инк. | Гуманизированные анти-тфр-бета-антитела |
| US7785903B2 (en) | 2004-04-09 | 2010-08-31 | Genentech, Inc. | Variable domain library and uses |
| CN1942483B (zh) | 2004-04-13 | 2012-09-26 | 弗·哈夫曼-拉罗切有限公司 | 抗p型选凝素抗体 |
| US7501121B2 (en) | 2004-06-17 | 2009-03-10 | Wyeth | IL-13 binding agents |
| US20070048785A1 (en) | 2004-06-09 | 2007-03-01 | Lin Laura L | Anti-IL-13 antibodies and complexes |
| AR049390A1 (es) | 2004-06-09 | 2006-07-26 | Wyeth Corp | Anticuerpos contra la interleuquina-13 humana y usos de los mismos |
| TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
| KR101270829B1 (ko) | 2004-09-23 | 2013-06-07 | 제넨테크, 인크. | 시스테인 유전자조작 항체 및 접합체 |
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| EP1814615B1 (en) | 2004-11-24 | 2015-10-28 | SHL Group AB | Injection device |
| EP2526987A3 (en) | 2005-06-01 | 2013-04-24 | SHL Group AB | Device for delivering medicament |
| DE602005008404D1 (de) | 2005-06-01 | 2008-09-04 | Shl Medical Ab | Medikamentenabgabevorrichtung |
| WO2007036745A2 (en) | 2005-09-30 | 2007-04-05 | Medimmune Limited | Interleukin-13 antibody composition |
| MY144906A (en) | 2005-10-21 | 2011-11-30 | Novartis Ag | Human antibodies against il13 and therapeutic uses |
| EP1957531B1 (en) | 2005-11-07 | 2016-04-13 | Genentech, Inc. | Binding polypeptides with diversified and consensus vh/vl hypervariable sequences |
| EP1973951A2 (en) | 2005-12-02 | 2008-10-01 | Genentech, Inc. | Binding polypeptides with restricted diversity sequences |
| WO2007134050A2 (en) | 2006-05-09 | 2007-11-22 | Genentech, Inc. | Binding polypeptides with optimized scaffolds |
| EP2059533B1 (en) | 2006-08-30 | 2012-11-14 | Genentech, Inc. | Multispecific antibodies |
| US20080226635A1 (en) | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
| EP2114451A2 (en) | 2007-01-09 | 2009-11-11 | Wyeth a Corporation of the State of Delaware | Anti-il-13 antibody formulations and uses thereof |
| CN100592373C (zh) | 2007-05-25 | 2010-02-24 | 群康科技(深圳)有限公司 | 液晶显示面板驱动装置及其驱动方法 |
| SI2235064T1 (sl) | 2008-01-07 | 2016-04-29 | Amgen Inc. | Metoda za izdelavo heterodimernih molekul - protitelesa fc z uporabo elektrostatičnih usmerjevalnih učinkov |
| FR2944448B1 (fr) | 2008-12-23 | 2012-01-13 | Adocia | Composition pharmaceutique stable comprenant au moins un anticorps monodonal et au moins un polysacharide amphiphile comprenant des substituants derives d'alcools hydrofobes ou d'amines hydrophobes. |
| JP6005657B2 (ja) | 2010-12-16 | 2016-10-12 | ジェネンテック， インコーポレイテッド | Ｔｈ２阻害に関連する診断及び治療 |
| AU2013204894B2 (en) * | 2010-12-16 | 2016-11-10 | Genentech, Inc. | Diagnosis and treatments relating to TH2 inhibition |
| EP2720737B1 (en) | 2011-06-17 | 2017-01-04 | SHL Group AB | Injection device |
| WO2012173553A1 (en) | 2011-06-17 | 2012-12-20 | Shl Group Ab | Injection device |
| LT3091029T (lt) * | 2011-10-31 | 2023-02-27 | F. Hoffmann-La Roche Ag | Anti-il13 antikūno kompozicijos |
| HRP20181227T1 (hr) | 2012-09-07 | 2018-10-05 | Regeneron Pharmaceuticals, Inc. | Metode za liječenje atopijskog dermatitisa primjenom antagonista il-4r |
| WO2014165771A2 (en) | 2013-04-05 | 2014-10-09 | Genentech, Inc. | Anti-il-4 antibodies and bispecific antibodies and uses thereof |
| EP3099323A4 (en) * | 2014-01-27 | 2017-10-04 | Medlmmune, LLC | Dipeptidyl peptidase-4 (dpp4/cd26) as a peripheral biomarker of il-13 activation in asthmatic lung |
| CA2977285A1 (en) * | 2015-03-16 | 2016-09-22 | F. Hoffmann-La Roche Ag | Methods of detecting and quantifying il-13 and uses in diagnosing and treating th2-associated diseases |
| CA3031589C (en) * | 2016-09-23 | 2025-05-06 | Genentech, Inc. | USES OF IL-13 ANTAGONISTS FOR THE TREATMENT OF ATOPIC DERMATITIS |
-
2017
- 2017-09-22 CA CA3031589A patent/CA3031589C/en active Active
- 2017-09-22 EP EP17780280.8A patent/EP3528838B1/en active Active
- 2017-09-22 KR KR1020197007162A patent/KR102557643B1/ko active Active
- 2017-09-22 NZ NZ790629A patent/NZ790629A/en unknown
- 2017-09-22 TW TW106132523A patent/TWI787203B/zh active
- 2017-09-22 JP JP2019515636A patent/JP6995844B2/ja active Active
- 2017-09-22 RU RU2019103943A patent/RU2752785C2/ru active
- 2017-09-22 EP EP23182855.9A patent/EP4268845A3/en active Pending
- 2017-09-22 RS RS20230712A patent/RS64550B1/sr unknown
- 2017-09-22 CN CN201780058200.4A patent/CN109715201A/zh active Pending
- 2017-09-22 MX MX2019002672A patent/MX2019002672A/es unknown
- 2017-09-22 PT PT177802808T patent/PT3528838T/pt unknown
- 2017-09-22 DK DK17780280.8T patent/DK3528838T5/da active
- 2017-09-22 LT LTEPPCT/US2017/052891T patent/LT3528838T/lt unknown
- 2017-09-22 PL PL17780280.8T patent/PL3528838T3/pl unknown
- 2017-09-22 ES ES17780280T patent/ES2958593T3/es active Active
- 2017-09-22 WO PCT/US2017/052891 patent/WO2018057849A1/en not_active Ceased
- 2017-09-22 SG SG11201900845YA patent/SG11201900845YA/en unknown
- 2017-09-22 IL IL265473A patent/IL265473B2/en unknown
- 2017-09-22 UA UAA201902409A patent/UA124269C2/uk unknown
- 2017-09-22 HU HUE17780280A patent/HUE063135T2/hu unknown
- 2017-09-22 SI SI201731388T patent/SI3528838T1/sl unknown
- 2017-09-22 AU AU2017330405A patent/AU2017330405B2/en active Active
- 2017-09-22 HR HRP20231015TT patent/HRP20231015T1/hr unknown
- 2017-09-22 FI FIEP17780280.8T patent/FI3528838T3/fi active
-
2019
- 2019-03-18 US US16/356,309 patent/US11434286B2/en active Active
-
2022
- 2022-08-08 US US17/882,932 patent/US20220372131A1/en active Pending
-
2023
- 2023-09-13 CY CY20231100495T patent/CY1126255T1/el unknown
-
2024
- 2024-03-21 US US18/612,141 patent/US20240228606A1/en active Pending
- 2024-04-29 NL NL301269C patent/NL301269I2/nl unknown
- 2024-04-29 LT LTPA2024512C patent/LTC3528838I2/lt unknown
- 2024-04-29 FR FR24C1017C patent/FR24C1017I2/fr active Active
- 2024-04-30 FI FIC20240013C patent/FIC20240013I1/fi unknown
- 2024-04-30 HU HUS2400011C patent/HUS2400011I1/hu unknown
- 2024-05-29 CY CY2024013C patent/CY2024013I1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3528838T3 (da) | Anvendelser af anti-IL-13-antistoffer til behandling af atopisk dermatitis | |
| IL283965A (en) | Antibodies against cd73 and uses thereof | |
| EP3426686C0 (en) | Humanized Anti-PACAP Antibodies and Their Uses | |
| DK3490582T3 (da) | Sammensætninger til anvendelse i behandling af myelofibrose | |
| KR20180084817A (ko) | 항-siglec-9 항체 및 이의 이용 방법 | |
| LT3280441T (lt) | Anti-sortilino antikūnai ir jų naudojimo būdai | |
| DK3253865T3 (da) | Fremgangsmåder til forbedring af virkningen af terapeutiske immunceller | |
| ME03558B (me) | Molekuli anti-lag-3 antiтela i njihove upotrebe | |
| IL246693B2 (en) | Antibody molecules to tim-3 and uses thereof | |
| IL258245A (en) | Anti-variant fc-region antibodies and methods of use | |
| LT3215532T (lt) | Anti-tim3 antikūnai ir jų naudojimo būdai | |
| DK3248986T3 (da) | Variable immunoglobulindomæner | |
| LT3148579T (lt) | Anti-gitr antikūnai ir jų panaudojimo būdai | |
| LT3295951T (lt) | Anti-pvrig antikūnai ir naudojimo būdai | |
| LT3250610T (lt) | Fcrn antikūnai ir jų panaudojimo būdai | |
| FR3018941B1 (fr) | Pilotage de vehicules en convoi | |
| IL247002A0 (en) | Anti-il-17/il-13 bispecific antibodies and their uses | |
| EP3835319C0 (en) | Humanized Anti-ACTH Antibodies and Their Use | |
| DK3481846T3 (da) | 11-substituerede 24-hydroxysteroler til anvendelse til behandling af nmda-relaterede tilstande | |
| DK4339615T3 (da) | Anti-PD-1-antistof til anvendelse i behandlingen af kræft | |
| DK3524255T3 (da) | Sammensætning til behandling af acne | |
| IL282201B (en) | Anti-tenascin c antibodies and uses thereof | |
| DK3164123T3 (da) | Hidtil ukendte anvendelser af benzylidenguanidinderivater til behandling af proteopatier | |
| DK3236960T3 (da) | Fluralaner til anvendelse i behandling af demodicose | |
| DK3478719T6 (da) | Anvendelse af anti-sclerostin-antistoffer i behandlingen af osteogenesis imperfecta |